Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Lilly bags FDA okay for Wegovy pill rival orforglipron

 April 1, 2026

Pharmaphorum

Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill.

RegulatoryMetabolic & GLP-1Read full story

Post navigation

Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry →
← FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com